Acquiring Company
Gilead Sciences
Acquired Company
MacroGenics
Foster CityRockvilleBiotechnologyHealth CareTherapeuticsBiopharmaManufacturingBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
Gilead Sciences has agreed to acquire MacroGenics in an all-cash transaction valued at approximately $1.7 billion. This acquisition follows the FDA approval of MacroGenics' cancer drug Vyloy, which targets Merkel cell carcinoma. The deal aims to integrate MacroGenics' capabilities into Gilead’s existing oncology portfolio. The transaction highlights a strategic focus on expanding Gilead's offerings in solid tumors.
Who to call at Gilead Sciences, and when
When Gilead Sciences changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Gilead Sciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Gilead Sciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Gilead Sciences. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Gilead Sciences makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired MacroGenics?
MacroGenics was acquired by Gilead Sciences, based in Foster City. The deal was reported on May 19, 2026. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. Gilead Sciences is publicly traded (GILD) and operates in Biotechnology.
When did Gilead Sciences acquire MacroGenics?
Gilead Sciences's acquisition of MacroGenics was reported on May 19, 2026. Gilead Sciences has agreed to acquire MacroGenics in an all-cash transaction valued at approximately $1.7 billion. This acquisition follows the FDA approval of MacroGenics' cancer drug Vyloy, which targets Merkel cell carcinoma. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does MacroGenics do?
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative antibody-based therapeutics for the treatment of cancer. It is publicly traded (MGNX), operating in Manufacturing, and is based in Rockville.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.